In last trading session, Kazia Therapeutics Limited ADR (NASDAQ:KZIA) saw 64978.0 shares changing hands with its beta currently measuring 2.12. Company’s recent per share price level of $1.69 trading at -$0.06 or -3.43% at ring of the bell on the day assigns it a market valuation of $5.63M. That closing price of KZIA’s stock is at a discount of -834.91% from its 52-week high price of $15.80 and is indicating a premium of 0.59% from its 52-week low price of $1.68. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.15 million shares which gives us an average trading volume of 134.17K if we extend that period to 3-months.
For Kazia Therapeutics Limited ADR (KZIA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Kazia Therapeutics Limited ADR (NASDAQ:KZIA) trade information
Upright in the red during last session for losing -3.43%, in the last five days KZIA remained trading in the red while hitting it’s week-highest on Thursday, 01/02/25 when the stock touched $1.69 price level, adding 13.0% to its value on the day. Kazia Therapeutics Limited ADR’s shares saw a change of -4.52% in year-to-date performance and have moved -4.52% in past 5-day. Kazia Therapeutics Limited ADR (NASDAQ:KZIA) showed a performance of -61.42% in past 30-days. Number of shares sold short was 18773.0 shares which calculate 0.11 days to cover the short interests.
Kazia Therapeutics Limited ADR (KZIA) estimates and forecasts
Statistics highlight that Kazia Therapeutics Limited ADR is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -74.71% of value to its shares in past 6 months, showing an annual growth rate of 50.45% while that of industry is 17.00. Apart from that, the company came raising its revenue forecast for fiscal year 2025.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 11.47% during past 5 years.
Kazia Therapeutics Limited ADR (NASDAQ:KZIA)’s Major holders
Investors also watch the number of corporate investors in a company very closely, which is 7.06% institutions for Kazia Therapeutics Limited ADR that are currently holding shares of the company. MORGAN STANLEY is the top institutional holder at KZIA for having 0.2 million shares of worth $45967.0. And as of 2024-06-30, it was holding 0.8386 of the company’s outstanding shares.
The second largest institutional holder is BNP PARIBAS ARBITRAGE, SNC, which was holding about 63568.0 shares on 2024-06-30. The number of shares represents firm’s hold over 0.2651 of outstanding shares, having a total worth of $14532.0.
